SCT, secretin, 6343

N. diseases: 230; N. variants: 0
Disease: Neoplasm, Residual ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 Biomarker phenotype BEFREE Maintenance therapy is started after SCT without detectable disease, while preemptive therapy is triggered by the detection of minimal residual disease (MRD). 30038353 2019
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 Biomarker phenotype BEFREE Our findings suggest that haplo-SCT with FM conditioning regimen and PTCy-based GVHD prophylaxis has a protective effect, and may potentially abrogate the inferior outcomes of MRD positivity for patients with AML. 31595538 2019
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 Biomarker phenotype BEFREE Our study indicated that the combination of cytogenetic classification and MRD monitoring correlated with outcome of auto- versus allo-SCT and might help the choice between the two types of SCT for adults with primary AML, which is of significance for patients with expected intermediate prognosis in the current scenario. 28189799 2017
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 Biomarker phenotype BEFREE The RR after SCT was 15% (12/81) in pre-SCT MRD-WT1 negative cases and 44% (18/41) in MRD-WT1 positive cases (p=0.00073). 29096332 2017
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 Biomarker phenotype BEFREE We analyzed the outcome of allo-SCT in a population of FLT3-positive AML patients according to molecular MRD at the pretransplantation workup, assessed by the quantitative expression evaluation of the panleukemic marker Wilms' tumor (WT1) gene. 28159598 2017
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 Biomarker phenotype BEFREE We investigated the prognostic relevance of IKZF1 deletions in 118 adult Ph-positive ALL patients who had minimal residual disease (MRD) data under a uniform treatment of allo-SCT following first-line imatinib-based chemotherapy. 25501350 2015
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 Biomarker phenotype BEFREE The minimal residual disease (MRD) status evaluated by sensitive polymerase chain reaction prior to allo-SCT did not influence the OS rate (77 vs 54%, p = 0.28) and leukemia-free survival rate (69 vs 51%, p = 0.48), irrespective of the conditioning intensity. 26475283 2015
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 Biomarker phenotype BEFREE MRD negativity predicted lasting remission independent of allo-SCT (N = 7) or non-allo-SCT (N = 9). 22458420 2012
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 Biomarker phenotype BEFREE In adolescents and young adults, for whom intensified pediatric protocols show promise for improving outcomes, minimal residual disease may be helpful for making the decision to conduct allo-SCT during first CR. 21854085 2012
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 Biomarker phenotype BEFREE Monitoring of minimal residual disease (MRD) after allogeneic (allo)-SCT for myelofibrosis (MF) allows recognizing the depth of remission and thus guides application of appropriate therapeutic interventions. 20062088 2010
CUI: C0242596
Disease: Neoplasm, Residual
Neoplasm, Residual 		0.100 Biomarker phenotype BEFREE B-cell reconstitution after allogeneic SCT impairs minimal residual disease monitoring in children with ALL. 18490915 2008